Abstract
Fludarabine Phosphate (FP), the 2-fluoro, 5'phosphate derivative of adenosine arabinoside (ara-A), was studied in 18 patients with advanced renal cell carcinoma. These patients had measurable disease and had not received chemotherapy. FP was administered at a loading dose of 20 mg/m2 followed by a 48-hour infusion at 30 mg/m2/day given every 21 days. There were no complete or partial responses seen. Toxicity was mainly hematologic, with leukopenia most commonly observed. FP given in this manner had no activity in advanced renal cell carcinoma.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antimetabolites, Antineoplastic / adverse effects
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Arabinonucleotides / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy*
-
Drug Evaluation
-
Female
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Vidarabine Phosphate / adverse effects
-
Vidarabine Phosphate / analogs & derivatives
-
Vidarabine Phosphate / therapeutic use*
Substances
-
Antimetabolites, Antineoplastic
-
Arabinonucleotides
-
Vidarabine Phosphate
-
fludarabine phosphate